Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 ANNOUNCED POSITIVE LONG-TERM SEVASEMTEN DATA DEMONSTRATING SUSTAINED FUNCTIONAL STABILIZATION IN BECKER MUSCULAR DYSTROPHY (BECKER) UP TO 3.5 YEARS OF FOLLOW-UP   CIRRUS-HCM 12-WEEK DATA OF EDG-7500 IN OBSTRUCTIVE AND NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) EXPECTED IN Q2 2026   PIVOTAL GRAND CANYON RESULTS FOR SEVASEMTEN IN BECKER EXPECTED IN Q4 2026  BOULDER, COLO., MAY 7, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AND RECENT BUSINESS HIGHLIGHTS.

EDGEWISE THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND ADVANCES CLINICAL PROGRAMS IN MUSCULAR DYSTROPHY AND CARDIOVASCULAR INDICATIONS

BOULDER, COLO., MAY 4, 2026 /PRNEWSWIRE/ --EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY"), (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR MUSCULAR DYSTROPHIES AND SERIOUS CARDIAC CONDITIONS, TODAY ANNOUNCED THAT ON APRIL 30, 2026, EDGEWISE GRANTED INDUCEMENT STOCK OPTIONS TO PURCHASE A TOTAL OF 266,000 SHARES OF EDGEWISE'S COMMON STOCK TO 9 NEW NON-EXECUTIVE EMPLOYEES IN CONNECTION WITH THE COMMENCEMENT OF THEIR EMPLOYMENT, PURSUANT TO EDGEWISE'S 2024 INDUCEMENT EQUITY INCENTIVE PLAN (THE "INDUCEMENT PLAN").

EDGEWISE THERAPEUTICS REPORTS INDUCEMENT GRANTS AS PERMITTED BY THE NASDAQ LISTING RULES

BOULDER, COLO., APRIL 1, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY"), (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR MUSCULAR DYSTROPHIES AND SERIOUS CARDIAC CONDITIONS, TODAY ANNOUNCED THAT ON MARCH 31, 2026, EDGEWISE GRANTED INDUCEMENT STOCK OPTIONS TO PURCHASE A TOTAL OF 72,000 SHARES OF EDGEWISE'S COMMON STOCK TO 4 NEW NON-EXECUTIVE EMPLOYEES IN CONNECTION WITH THE COMMENCEMENT OF THEIR EMPLOYMENT, PURSUANT TO EDGEWISE'S 2024 INDUCEMENT EQUITY INCENTIVE PLAN (THE "INDUCEMENT PLAN").

THE MESA DATA SHOW STABILIZATION OF FUNCTION IN PARTICIPANTS ON SEVASEMTEN VERSUS THE PREDICTED FUNCTIONAL DECLINE OBSERVED IN BECKER NATURAL HISTORY STUDIES   DATA REINFORCE PRIOR CLINICAL FINDINGS OF SEVASEMTEN IN BECKER, A RARE DISEASE WITH NO APPROVED TREATMENTS  THE GRAND CANYON PLACEBO-CONTROLLED PIVOTAL COHORT IS ON TRACK TO READOUT IN 4Q 2026  BOULDER, COLO., MARCH 10, 2026 /PRNEWSWIRE/ --EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY, TODAY PRESENTED AT THE 2026 MDA CLINICAL AND SCIENTIFIC CONFERENCE, LONG-TERM DATA FROM ITS MESA OPEN-LABEL EXTENSION STUDY OF SEVASEMTEN IN BECKER MUSCULAR DYSTROPHY (BECKER), A DEVASTATING GENETIC DISORDER WITH NO APPROVED THERAPEUTIC INTERVENTIONS.

EDGEWISE ANNOUNCES POSITIVE LONG-TERM SEVASEMTEN DATA DEMONSTRATING SUSTAINED FUNCTIONAL STABILIZATION IN BECKER MUSCULAR DYSTROPHY THROUGH 3.5 YEARS OF FOLLOW-UP

BOULDER, COLO., MARCH 4, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT EDGEWISE LEADERSHIP WILL PRESENT AT THE LEERINK GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, MARCH 11, 2026, AT 1:40 P.M.

EDGEWISE THERAPEUTICS TO PRESENT AT THE LEERINK GLOBAL HEALTHCARE CONFERENCE ON MARCH 11, 2026

BOULDER, COLO., MARCH 3, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED ITS PARTICIPATION AT THE 2026 MUSCULAR DYSTROPHY ASSOCIATION (MDA) CLINICAL AND SCIENTIFIC CONFERENCE.

EDGEWISE THERAPEUTICS TO PRESENT ON SEVASEMTEN FOR THE TREATMENT OF BECKER MUSCULAR DYSTROPHY AT THE 2026 MDA CLINICAL AND SCIENTIFIC CONFERENCE

BOULDER, COLO., MARCH 2, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY"), (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR MUSCULAR DYSTROPHIES AND SERIOUS CARDIAC CONDITIONS, TODAY ANNOUNCED THAT ON FEBRUARY 27, 2026, EDGEWISE GRANTED INDUCEMENT STOCK OPTIONS TO PURCHASE A TOTAL OF 51,000 SHARES OF EDGEWISE'S COMMON STOCK TO 3 NEW NON-EXECUTIVE EMPLOYEES IN CONNECTION WITH THE COMMENCEMENT OF THEIR EMPLOYMENT, PURSUANT TO EDGEWISE'S 2024 INDUCEMENT EQUITY INCENTIVE PLAN (THE "INDUCEMENT PLAN").

 CIRRUS-HCM 12-WEEK DATA OF EDG-7500 IN OBSTRUCTIVE AND NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) EXPECTED IN H1 2026   PHASE 1 HEALTHY ADULT TRIAL DATA OF EDG-15400 AND PLANS FOR HEART FAILURE STUDIES EXPECTED IN H1 2026   PIVOTAL GRAND CANYON RESULTS FOR SEVASEMTEN IN BECKER MUSCULAR DYSTROPHY (BECKER) EXPECTED IN Q4 2026  BOULDER, COLO., FEB. 26, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR OF 2025 AND RECENT BUSINESS HIGHLIGHTS.

EDGEWISE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS WITH STRONG PROGRESS ACROSS MUSCULAR DYSTROPHY AND CARDIOVASCULAR PROGRAMS

BOULDER, COLO., FEB. 5, 2026 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC., (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT BEHRAD DERAKHSHAN, PH.D.

EDGEWISE THERAPEUTICS TO PRESENT AT THE GUGGENHEIM EMERGING OUTLOOK: BIOTECH SUMMIT 2026 ON FEBRUARY 12, 2026

BOULDER, COLO., FEB. 2, 2026 /PRNEWSWIRE/ --EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY"), (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR MUSCULAR DYSTROPHIES AND SERIOUS CARDIAC CONDITIONS, TODAY ANNOUNCED THAT ON JANUARY 30, 2025, EDGEWISE GRANTED INDUCEMENT STOCK OPTIONS TO PURCHASE A TOTAL OF 198,250 SHARES OF EDGEWISE'S COMMON STOCK TO 7 NEW NON-EXECUTIVE EMPLOYEES IN CONNECTION WITH THE COMMENCEMENT OF THEIR EMPLOYMENT, PURSUANT TO EDGEWISE'S 2024 INDUCEMENT EQUITY INCENTIVE PLAN (THE "INDUCEMENT PLAN").

Edgewise Therapeutics, Inc.

EWTX

Price

Financial Reports

No items found.

Press Releases

Edgewise Therapeutics, Inc.

EWTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

EWTX